AMRA Medical

04/12/2025

AMRA Medical To Present New Research on Fat Distribution & Muscle Composition in Heart Failure at the 22nd Global CVCT Forum

We are excited to share that we will be attending and presenting at the 22nd iteration of the CVCT - Cardiovascular Clinical Trialists Forum, happening December 8-10 at The Mayflower Hotel in Washington, D.C.!

AMRA is looking forward to contributing to the conversation at CVCT 2025, most notably by sharing results from a recent study done in collaboration with Javed Butler, MD, MPH, MBA from the Baylor Scott & White Research Institute, and Linköping University. Given the lack of normative data regarding body composition in individuals with heart failure (HF), the study aimed to provide reference data for fat distribution and muscle composition in 185 participants with HF based on the UK Biobank imaging study.

The results showed that HF was characterized by subtle but consistent alterations in fat distribution and marked muscle derangements, rather than overt obesity or sarcopenia, and suggest that traditional indices for obesity and sarcopenia underestimate the burden of metabolic and musculoskeletal derangements in HF. This study comes at a pivotal time in the heart failure trials space as ongoing studies assess the use of weight-loss therapies for management within HF populations, with associated concerns surrounding loss of muscle mass and onset of sarcopenia.

Are you attending CVCT 2025? You can learn more about the study and its findings by visiting us at our poster, presented by Jennifer Linge, PhD, or by connecting with us at info@amramedical.com to find a time to discuss with our team on site in D.C.. We would love to see you there and talk about how AMRA’s various offerings can help move your science and clinical care practice forward, in cardiovascular disease and beyond.

01/12/2025

The 2nd Annual Innovation in Obesity Therapeutics Summit is here!

AMRA’s CEO, Dr. Olof Dahlqvist Leinhard, discusses how transformative MRI-based body composition methods and AMRA’s unique biomarkers are redefining obesity drug trials.

➜ "MRI-based Body Composition Reimagined: Building a New Foundation for Treatment Differentiation Beyond Weight Loss"
➜ Olof Dahlqvist Leinhard, PhD
➜ December 3rd, 2:10pm

This talk covers:

‣ FDA-cleared MRI-based body composition analysis provides a new standard for muscle and fat quantification enabling translation from population studies and clinical trials all the way into healthcare.

‣ Studies on Personalized Fat and Muscle Z-score biomarkers show improved prediction of outcomes and that weight- and BMI-invariant treatment effects can be detected.

‣ Understanding loss of muscle mass and shifts in fat distribution in the context of weight reduction and exploring the varying effects of liraglutide and tirzepatide in recent clinical trials.

Read about the talk and the conference here: https://tinyurl.com/3hk5ft9k

If you would like to connect, reach out to Leanna Kellerman via info@amramedical.com.

Interested in this topic? Read our Insights Article to learn more:
https://tinyurl.com/39zewvzs

20/11/2025

AMRA is at LINK-dagarna this week — Linköping University’s student career fair — meeting the next generation of bright minds in IT and Data 🚀

04/11/2025

Explore AMRA’s Latest Insights In Liver Disease Research @ AASLD 2025!

November is upon us and that means it is once again time for AASLD’s The Liver Meeting®! This year, the AMRA team is thrilled to be in attendance to share updates on Saturday, November 8th from three studies using our MRI-based muscle assessment biomarkers in MASH cirrhosis research, done in collaboration with our colleagues at Virginia Commonwealth University (VCU), Indiana University (IU), and Linköping University (LiU):

➡️ “Reduced Fat and Muscle Volumes in Decompensated Cirrhosis: A Whole-Body MRI Study” | Poster #2470

➡️ “Muscle Composition Matters: MRI-Based Myosteatosis Strongly Correlates with Physical Function in Cirrhosis” | Poster #2384

➡️ “Muscle quality, defined by low muscle volume and muscle fat index on MRI, is worse in decompensated NASH cirrhosis, but not in compensated MASH cirrhosis” | Poster #2642 | Presented by Dr. Samala, IU

These poster presentations highlight AMRA’s evaluation of muscle wasting in MASH and cirrhosis. Using our muscle assessment score (MAsS) biomarkers, the studies show that the prevalence of the adverse muscle composition phenotype, defined by low muscle volume z-score and high muscle fat infiltration, increases drastically in decompensated MASH cirrhosis.

In addition, strong correlations between the MAsS biomarkers and standard physical function tests in patients with decompensated cirrhosis is demonstrated. Collectively, these studies underscore the value of AMRA’s MRI-based MAsS biomarkers for use in evaluating muscle wasting in liver disease studies.

If you’ll be in DC next week, reach out to any of our team members - Mikael Forsgren, Maria Rydfjord, or Conrad Maurais, - who will be in attendance at The Liver Meeting®. Or contact info@amramedical.com to set up some time to discuss how AMRA’s MRI-based fat and muscle biomarkers can help you transform your trials in MASH, cirrhosis, and beyond.

We can’t wait to see you in DC!

30/10/2025

Connect With AMRA at MYO-MRI 2025!

The biannual conference, running this year from November 9th-11th in Berlin, Germany, brings together leading experts in neuromuscular imaging and disease to exchange ideas and discuss the latest research in the field.
This year’s focus on muscle MRI as an outcome measure in clinical trials underscores the growing importance of MRI-based measures in advancing neuromuscular disease (NMD) research and therapeutic development.

As the global leader in quantitative MRI analysis within neuromuscular disease trials, we're proud to contribute to the conversation at this year’s conference. AMRA’s own Markus Karlsson, PhD will be joining the roundtable session, “Unmet Need for Pharmaceutical Trials,” as an expert discussant to provide AMRA’s perspective on how imaging approaches can continue to be used to improve clinical trial outcomes in NMDs.

Will you be at MYO-MRI 2025? We’d love to connect and discuss how AMRA’s advanced MRI-based biomarkers can help enhance sensitivity and reproducibility in your neuromuscular trials.

Reach out to our Chief Globalization Officer, Leanna Kellerman, or to Markus Karlsson who will both be on-site in Berlin for MYO-MRI 2025 to schedule a time to meet – or send us a note at info@amramedical.com.

28/10/2025

Come Chat with AMRA at BIO-EUROPE 2025!

AMRA is excited to be joining industry leaders, innovators, and partners at the BIO-EUROPE 2025 conference in Vienna, taking place November 3–5! BIO-EUROPE is one of the world’s premier life science partnering events, bringing together stakeholders from all parts of the industry to build relationships that help drive life sciences organizations and bioinnovation forward.

Our Chief Globalization Officer, Leanna Kellerman, will be on-site to connect and discuss how AMRA’s advanced MRI-based fat distribution and muscle composition biomarker solutions can help advance your science and clinical research efforts.

If you’re attending BIO-EUROPE, we’d love to meet you in Vienna! Reach out to Leanna Kellerman or to info@amramedical.com to get in touch with us ahead of the event. We can’t wait to see you there!

22/10/2025

Meet AMRA at The Obesity Society’s ObesityWeek® 2025, taking place November 4–7 in Atlanta, GA!

This year’s focus — “Obesity as a Chronic Disease” — highlights the importance of long-term, evidence-based strategies for prevention, care, and management.

As the gold standard for fat distribution and muscle composition analytics, AMRA is looking forward to holding discussions around obesity as it emerges as a chronic condition at this year’s conference, and learning more about how we can continue to utilize our deep expertise and our MRI-based measures to help advance research and clinical care.

Will you be at ObesityWeek® 2025? Get in touch with our team members who will be on site in Atlanta, Conrad Maurais, and Olof Dahlqvist Leinhard, to connect and learn more about how AMRA can help you drive progress in obesity treatment and care forward! You can reach us at info@amramedical.com.

13/10/2025

We’re honored to be featured in Corren following our inclusion in TIME Magazine’s list of the world’s top health tech companies for 2025!

A big thank you to our amazing team and partners who make this possible. Together, we’re transforming how the world understands and treats obesity. 💪🌍

Med sina mediciner mot övervikt har bolag som Novo Nordisk och Eli Lilly blivit omtalade världen över. I Linköping finns ett företag som varit med i...

09/10/2025

AMRA Medical at the Nordic Network SLD 2025 Meeting!

This week, AMRA Medical’s very own Mikael Forsgren, PhD, and Olof Dahlqvist Leinhard, PhD, are attending the Nordic Network in Steatotic Liver Disease (SLD) Meeting, taking place here at home on the 9th and 10th of October in Stockholm, Sweden!

The by-invitation initiative brings together leading experts with a range of backgrounds from across the Nordic region to foster collaboration, strengthen research networks, and advance healthcare and public engagement of steatotic liver disease.

As a major contributor to various efforts in liver and metabolic disease research, AMRA is proud to add to this growing dialogue on liver health at this week’s meeting. If you’ll be at the Nordic SLD Meeting and want to connect with Mikael or Olof – send us a note here or reach out to info@amramedical.com!

25/09/2025

Catch Up With AMRA at The 2025 Global CMT Research Foundation This Week!

We’re excited to be in attendance at the 2025 edition of the Global Charcot-Marie-Tooth (CMT) Research Convention, which runs until September 27th in Cambridge, Massachusetts!

Our own Conrad Maurais will be on-site to share insights about AMRA’s MRI-based technology and solutions in clinical research. If you’re interested in getting in touch with Conrad, reach out via info@amramedical.com.

Hosted by the CMT Research Foundation, the event brings together patients, scientists, biopharma leaders, investors, and regulators with a shared mission: advancing treatments for Charcot-Marie-Tooth disease. CMT 2025 will feature scientific sessions designed for researchers, investors, and industry experts working to deepen understanding of CMT and drive progress toward a cure. You can learn more about CMT 2025 here: https://cmtconvention.cmtrf.org/

We hope to see you there!